Sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs) are two large classes of drugs that can markedly improve renal and cardiovascular outcomes in patients with diabetes and CKD 89. Here, SLC5A2 is linked to diabetes mellitus.